After multiple delays, the amendments to the Patented Medicines Review Board regulations will finally come into force on July 1, 2022. Last week, Health Minister Jean-Yves Duclos announced the federal government will proceed with the amendments to provide the PMPRB with new tools to protect Canadians from excessive prices for patented medicines. “This will improve access for […]
This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]
Some 8.4 million adult Canadians adults live with obesity and severe obesity has increased 455 per cent since 1985, according to Dr. Mary Forhan (pictured left), scientific director-elect of Obesity Canada, during a session supported by Desjardins Insurance at Benefits Canada‘s 2022 Chronic Disease at Work event in February. Although many believe that people can […]
On Dec. 15, the industry’s most popular drug benefits conference returned in a virtual format, highlighting the trends and opportunities for Canadian benefits plan sponsors to consider. Here’s what you missed: Using proactive drug plan design to ensure future sustainability Ensuring plan sponsors get value for money from their drug plans Patient support program insights […]
In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]
The drug pipeline is full of new medications that may be more effective but may also be more expensive than existing treatments. Although they could significantly improve a benefits plan member’s health, they could also render a plan unaffordable. “Because drugs represent a significant portion of group insurance plan costs, plan sponsors are concerned about […]
The coronavirus pandemic and the changing environment have impacted pharmaceutical manufacturer-sponsored patient support programs. Manufacturers offer patient support programs to help individuals access their medication and navigate the health-care system, according to Sandra Anderson, senior vice-president of commercialization and strategy at Innomar Strategies, speaking during a session at Benefits Canada‘s Face to Face in Drug […]
A growing number of organizations are moving beyond compliance to foster diversity, equity and inclusion in their workplaces. According to research, companies that have embraced a DEI strategy improved their bottom line with a 53 per cent return on equity, a 42 per cent return on sales, in addition to being 70 per cent more […]
The coronavirus pandemic is demonstrating that pharmacists are a key health-care provider, with one study finding nearly 75 per cent of pharmacists have had patients who sought care at the pharmacy because they were afraid of going to any other health-care setting. A panel during Benefits Canada‘s Face to Face in Drug Plan Management Forum in […]
The Canadian Drug Insurance Pooling Corp.’s high-cost drug framework provided coverage to almost 28,000 Canadians and their families where drug costs exceeded $10,000 annually in 2020. According to its results, the CDIPC estimated that its member insurance companies reimbursed claims associated with 54 new high-cost drugs including those for rare diseases. As well, based on past experience, […]